Clinical Development: Building An Evidence Foundation for Clinical Strategy and Protocol Design

Before the Trial Begins

The most consequential trial-design decisions get made weeks before a protocol exists, when an indication, a population, an endpoint strategy, and a comparator are still assumptions instead of commitments. This eBook shows Strategy and Planning teams how to test those assumptions against the relevant evidence while changing course is easier.

Most of what a protocol decision depends on already exists, spanning prior trials, treatment guidelines, competitive intelligence, and regulatory precedent. The obstacle is the time it takes one person to review that evidence manually, one paper and one trial at a time, not whether the evidence is available. That's how weak assumptions make it into protocols, when nobody has assembled the evidence before the decision gets locked in.

What's inside

• Where protocol risk starts. The three decisions that shape the rest of a protocol, covering indication, population and endpoint, and comparator.
• A worked example, start to finish. From a clinical study concept to a complete pre-protocol evidence brief.
• Why this isn't a general-purpose search problem. What changes when a platform reasons across structured biomedical sources with full source traceability.
• Two real customer stories. A half-day literature synthesis, and an orphan drug designation secured in half a day against a historical baseline of nearly a month.

What teams using this approach have found

"This took roughly half a day to produce a full draft of the regulatory submission. A comparable task on an earlier program had taken nearly a month of work. The designation was granted without any follow-up questions."— Clinical Development Director, Global Pharmaceutical Company

"Over the past year this has become one of the first tools I reach for when I need to get up to speed on a topic. Even modest time savings add up to a meaningful difference across a busy week."— Biomarker & Diagnostics Director, Global Pharmaceutical Company

Get the eBook to see what a traceable evidence brief looks like before the trial starts.

‍

‍